CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.000.00%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.91% | 2.53% | -63.07% | -51.57% | -75.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.91% | 147.05% | -73.47% | -73.82% | -85.92% |
| Operating Income | -73.91% | -147.05% | 73.47% | 68.65% | 78.59% |
| Income Before Tax | -230.52% | -147.69% | 54.29% | 78.56% | 80.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -230.52% | -147.69% | 54.29% | 78.56% | 80.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -230.52% | -147.69% | 54.29% | 78.56% | 80.73% |
| EBIT | -73.91% | -147.05% | 73.47% | 68.65% | 78.59% |
| EBITDA | -- | -112.76% | 85.36% | 73.10% | 85.80% |
| EPS Basic | 81.82% | 68.42% | 66.67% | 79.05% | 82.81% |
| Normalized Basic EPS | 85.71% | 66.67% | 65.38% | 65.85% | 82.50% |
| EPS Diluted | 81.82% | 68.42% | 66.67% | 79.05% | 82.81% |
| Normalized Diluted EPS | 85.71% | 66.67% | 65.38% | 65.85% | 82.50% |
| Average Basic Shares Outstanding | 2,255.59% | 723.76% | 36.92% | 3.58% | 12.07% |
| Average Diluted Shares Outstanding | 2,255.59% | 723.76% | 36.92% | 3.58% | 12.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |